Last reviewed · How we verify
ertapenem sodium (MK0826)
Ertapenem sodium is a carbapenem antibiotic that inhibits bacterial cell wall synthesis.
Ertapenem sodium is a carbapenem antibiotic that inhibits bacterial cell wall synthesis. Used for Complicated skin and skin structure infections, Complicated intra-abdominal infections, Community-acquired pneumonia.
At a glance
| Generic name | ertapenem sodium (MK0826) |
|---|---|
| Also known as | MK0826 |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | carbapenem antibiotic |
| Target | penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
It does this by binding to penicillin-binding proteins (PBPs) located inside the bacterial cell wall, resulting in the disruption of the cell wall synthesis and ultimately leading to bacterial cell death.
Approved indications
- Complicated skin and skin structure infections
- Complicated intra-abdominal infections
- Community-acquired pneumonia
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
- Headache
Key clinical trials
- Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia (PHASE2)
- A Platform Trial for Gram Negative Bloodstream Infections (NA)
- Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia (PHASE4)
- Cefotetan Therapy for Escherichia Coli Infections (PHASE2)
- Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care (PHASE4)
- Antibiotic Concentrations Among Critically Ill Patients
- Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? (PHASE4)
- Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ertapenem sodium (MK0826) CI brief — competitive landscape report
- ertapenem sodium (MK0826) updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI